YATHARTH · Health Care · 2026-08-21

Yatharth Hospital & Trauma Care Services Ltd

6.6★★ GoodStrong +6.9Stage 2 · wk 15In scan: Pullback Hunter · Prop ScanMARKET: BULL RISING · 2026-08-21
₹855.2
+0.86% today
₹8,240 Cr · Mid cap
About this companyHealth Care· Hospitals & Diagnostic Centres
Expand ▾

Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.

Visit company website →
P/E (TTM)
44.7
Forward 25.6
Earnings Growth (YoY)
+12.9%
Revenue +47.2%
ROE
+9.9%
Profit margin +14.2%
vs 52W High
-4.9%
₹550.8 lo₹898.8 hi
4.9% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 15
1w13w26w
Week 15 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
14.0%
200 DMA: ₹749.8 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.58x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +0.7% vs MA50 +1.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #39 of 84 Stage 2 stocks in Health Care by RS.
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
55.6%
20d Δ
-7.4pp
1M return
-2.8%
3M return
+2.0%
Industry Stage-2 % · last 20 days
Ranks #5 of 15 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-08-07 → 2026-08-21
S? 43w
S2 22w
S2 21w
S2 15w
2023-08-072026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 43w → S3 1w → S2 2w → S3 6w → S2 22w → S3 5w → S4 10w → S1 11w → S2 21w → S3 9w → S4 9w → S1 4w → S2 15w current
Total tracked: 158 weeks across 13 stage runs.
1M
+1.6%
3M
-0.8%
6M
+25.6%
YTD
+25.3%
1Y
+19.6%
Scan Membership
Pullback Hunter
Latest: 2026-08-21
Prop Scan
Latest: 2026-08-21
60 appearances in last 60 days. First seen: 2026-06-15.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 15 · Vol —x
2026-08-20S2
Wk 15 · Vol —x
2026-08-19S2
Wk 15 · Vol —x
2026-08-18S2
Wk 15 · Vol —x
2026-08-17S2
Wk 14 · Vol —x
2026-08-14S2
Wk 14 · Vol —x
2026-08-13S2
Wk 14 · Vol —x
2026-08-12S2
Wk 14 · Vol —x
2026-08-11S2
Wk 14 · Vol —x
2026-08-10S2
Wk 13 · Vol —x
2026-08-07S2
Wk 13 · Vol —x
2026-08-06S2
Wk 13 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹845.7
200 DMA
₹749.8
52W High
₹898.8
52W Low
₹550.8
5D Low
₹842.9
Resistance levels (recent highs)
20d High
₹898.8
60d High
₹898.8
120d High
₹898.8
250d High
₹898.8
Next resistance
+5.1%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.